Boundless Bio Announces Portfolio Prioritization and Runway Extension
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program
Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program
Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates focused on optimizing the Company's portfolio for patient impact and long-term value-creation.
Executive Summary
Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial.
Plans to evaluate BBI-355 and BBI-825 as a combination therapy in the POTENTIATE clinical trial, targeting initiation in the second half of 2025.
Declared BBI-940 as the development candidate for novel Kinesin program; IND submission on track for the first half of 2026.
Streamlined operations, extending the Company's expected cash runway into the first half of 2028, through proof-of-concept clinical milestones for each of its therapeutic programs.
'At Boundless, we're committed to delivering innovative therapies for patients with oncogene-amplified cancers through disciplined execution,' said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. 'By prioritizing the novel combination of BBI-355 and BBI-825, along with our exciting Kinesin program, BBI-940, we're concentrating our resources where we see the greatest potential to develop meaningful medicines. These decisions extend our operating runway into the first half of 2028, which should enable us to reach initial clinical milestones for these programs with our current capital.'
BBI-355 and BBI-825 Programs
Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial
Boundless has been investigating BBI-355, a novel, oral, selective CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers in its ongoing Phase 1/2 POTENTIATE clinical trial. In the trial, which explored different dose levels and dosing regimens, BBI-355 has demonstrated a narrow therapeutic index with continuous every other day dosing (Q2D), resulting from hematological toxicity at or near doses associated with clinical activity. The Company believes BBI-355's narrow therapeutic index makes it suboptimal for continued development as a single agent with continuous dosing. In addition, the combinations of BBI-355 with the EGFR inhibitor erlotinib, and with the FGFR inhibitor futibatinib, were not well-tolerated with Q2D dosing at the exposure levels believed to be required for robust, sustained anti-tumor activity. Based on these findings and market considerations, the Company has decided to discontinue further clinical development in the current arms of the POTENTIATE clinical trial.
Pursuing novel-novel combination for BBI-355 and BBI-825
Last year, Boundless announced its decision to not advance the STARMAP clinical trial of its novel, oral, selective ribonucleotide reductase (RNR) inhibitor, BBI-825. The decision was due, in part, to a lack of dose proportional pharmacokinetic exposure observed at steady-state as a result of BBI-825 inducing its own metabolism in trial subjects following continuous twice daily (BID) dosing. Based on recent studies, the Company believes that there is strong mechanistic rationale to combine BBI-825 with BBI-355 for synergistic anti-tumor activity as a replication stress combination therapy that does not require continuous dosing, nor involve overlapping toxicity. The novel/novel combination demonstrated preclinical evidence of synergistic cytotoxicity in cancer cell lines and tumor regression in mouse xenograft models using weekly dosing at exposures not associated with hematologic toxicity. The company will present additional scientific details supporting this decision during the live webcast on Tuesday, May 27.
Boundless plans to initiate clinical development of the BBI-355/BBI-825 combination in 2025 and expects to deliver initial proof-of-concept clinical data within its extended cash runway timeline.
Kinesin Program
Development candidate BBI-940 declared for novel Kinesin program
Boundless's novel Kinesin program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. The Company has discovered orally bioavailable, highly selective Kinesin degraders that have demonstrated potent anti-tumor activity in a range of cancer cell lines as well as single agent tumor regressions in mouse xenograft cancer models. The Company selected BBI-940 as its development candidate and reaffirmed that it expects to submit an Investigational New Drug (IND) application in the first half of 2026. Boundless expects to deliver initial proof-of-concept clinical data from BBI-940 within its extended cash runway timeline.
Operational Update
In connection with its portfolio prioritization, Boundless has streamlined its operations, resulting in an approximately one-third reduction of its workforce. The Company believes the combination of portfolio prioritization, streamlined operations, and its cash, cash equivalents, and short-term investments of $138.3 million as of March 31, 2025, will extend its operating runway into the first half of 2028 and through anticipated clinical proof-of-concept readouts for each of its therapeutic programs.
Mr. Hornby concluded, 'I want to personally thank our departing team members, whose valuable contributions have helped advance our science and build our company. Their work remains an integral part of our foundation as we continue our important mission for patients.'
Webcast and Conference Call Information
Boundless will host a live webcast and conference call on Tuesday, May 27 at 8:00 am ET to discuss these updates. To access the webcast and slides, please visit Events & Presentations in the Investors section of the Company's website at boundlessbio.com. A replay of the webcast will be available for 30 days following the event.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors. Boundless Bio's research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio's next ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) that has been evaluated in a Phase 1/2 clinical trial in cancer patients with resistance gene amplifications. Boundless Bio is also conducting IND-enabling studies of BBI-940, a potentially first-in-class orally bioavailable, highly selective Kinesin degrader. Boundless Bio is headquartered in San Diego, CA. For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.
Forward-Looking Statements
Boundless Bio cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include but are not limited to: our expected cash runway and the sufficiency thereof to fund operations through anticipated proof-of-concept clinical data readouts for each of our therapeutic programs; the timing of expected data readouts; submission of an IND application for BBI-940 and the timing thereof; our plans to discontinue the current arms of the POTENTIATE trial; the expected benefits of our portfolio prioritization; and the potential safety and therapeutic benefits of our ecDTx in treating patients with oncogene amplified cancers. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: we are early in our development efforts and our approach to discover and develop ecDTx to treat oncogene amplified cancers is novel and unproven; results from preclinical studies or early clinical trials not necessarily being predictive of future results; potential delays in the commencement, enrollment, data readouts or completion of clinical trials or preclinical studies or submission of an IND, including as a result of FDA feedback on our regulatory submission to support our planned clinical trial of the BBI-355 and BBI-825 combination; we may not realize the benefits expected from our portfolio prioritization and the streamlining of operations and workforce reduction, including our ability to conserve cash; our ability to retain remaining key personnel; our dependence on third parties in connection with clinical trials, preclinical studies, and manufacturing; unfavorable results from clinical trials or preclinical studies; we may expend our limited resources to pursue a particular ecDTx or combination therapy and fail to capitalize on ecDTx with greater development or commercial potential; unexpected adverse side effects or inadequate efficacy of our ecDTx that may limit their development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; regulatory developments in the United States and foreign countries; we may use our capital resources sooner than we expect; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in our annual report on Form 10-K for the year ended December 31, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
InvestorsRenee LeckTHRUST Strategic Communicationsrenee@thrustsc.com
MediaCarly Scadutocarly@carlyscadutoconsulting.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Finlay Minerals Announces Increase in Size of Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, June 4, 2025 /CNW/ - Finlay Minerals Ltd. (TSXV: FYL) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that due to strong investor interest it has increased the size of its non-brokered private placement (the "Private Placement"), previously announced on May 26, 2025, to raise up to $1,700,000. The Private Placement will consist of the issuance of any combination of: (i) common shares of the Company to be issued on a flow-through basis under the Income Tax Act (Canada) (each, a "FT Share") at a price of $0.11 per FT Share, and (ii) non-flow-through units of the Company (each, a "NFT Unit") at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of up to $1,700,000. The Private Placement is subject to a minimum offering amount of $500,000, to be raised through any combination of FT Shares and NFT Units. The Company also announces that it will use the gross proceeds from the issuance of FT Shares to incur "Canadian exploration expenses" that qualify as "flow-through critical mineral mining expenditures", as such terms are defined in the Income Tax Act (Canada). Each NFT Unit will be comprised of one non-flow-through common share of the Company (each, a "NFT Share") and one non-flow-through common share purchase warrant (a "Warrant"). Each Warrant will be exercisable by the holder thereof to acquire one NFT Share at an exercise price of $0.20 per NFT Share for a period of two years from the date of issuance of the Warrant (the "Warrant Expiry Date"), subject to acceleration. The Warrant Expiry Date may, at the Company's sole discretion, be accelerated if at any time following the Closing Date (as defined herein), the common shares of the Company trade at a daily volume-weighted average trading price above $0.30 per common share for a period of 30 consecutive trading days on the TSX Venture Exchange (the "TSXV") or on such other stock exchange where the majority of the trading occurs (the "Trading Target") and the Company provides notice to the Warrant holders by way of press release announcing that such Trading Target has been achieved, provided that the accelerated expiry date of the Warrants falls on the earlier of (unless exercised by the holder prior to such date) (the "Accelerated Expiry Date"): (i) the 30th day after the Company provides notice to the Warrant holders of its intention to accelerate the Warrant Expiry Date; and (ii) the Warrant Expiry Date. The failure of the Company to give notice in respect of a Trading Target will not preclude the Company from giving notice of any subsequent Trading Target. All Warrants that remain unexercised following the Accelerated Expiry Date shall immediately expire and all rights of holders of such Warrants shall be terminated without any compensation to such holders. The Company intends to use the gross proceeds of the Private Placement for exploration of the Company's SAY, JJB and Silver Hope properties, and for general working capital purposes, as more particularly described in the amended and restated offering document. Subject to compliance with applicable regulatory requirements, the Private Placement is being conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The securities issued to purchasers in the Private Placement will not be subject to a hold period under applicable Canadian securities laws. There is an amended and restated offering document related to the Private Placement that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this amended and restated offering document before making an investment decision. The closing of the Private Placement is expected to occur on or about June 9, 2025 (the "Closing Date"). The closing of the Private Placement is subject to certain closing conditions, including the approval of the TSXV. The Company may pay finder's fees in cash and securities to certain arm's length finders engaged in connection with the Private Placement, subject to the approval of the TSXV. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder. About Finlay Minerals Ltd. Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries. Finlay trades under the symbol "FYL" on the TSXV and under the symbol "FYMNF" on the OTCQB. For further information and details, please visit the Company's website at On behalf of the Board of Directors, Robert F. Brown,Executive Chairman of the Board & Director Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the terms and completion of the Private Placement, raising the minimum and maximum amounts of the Private Placement, the payment of finder's fees and issuance of finder's securities, the anticipated closing date and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay's proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements, and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law. SOURCE Finlay Minerals Ltd. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
F4 Announces 2025 Exploration Program and Private Placement of up to $1.5 Million
Kelowna, British Columbia--(Newsfile Corp. - June 4, 2025) - F4 Uranium Corp. (TSXV: FFU) (the "Company" or "F4") is pleased to announce the details of an exploration program for five of its mineral properties located in the Athabasca Basin region of Saskatchewan (the "Exploration Program") and a non-brokered private placement consisting of up to 15,000,000 common shares of the Company (the "FT Shares") that shall qualify as "flow-through shares" for the purposes of the Income Tax Act(Canada)(the "Tax Act") at a price of $0.10 per FT Share for gross proceeds of up to $1,500,000 (the "Private Placement"). Red Cloud Securities Inc. will be acting as a finder in connection with the Offering. The Exploration Program One of F4's key strengths is its 100% ownership of 17 different uranium mineral properties located in the Athabasca Basin region of Saskatchewan, Canada. The Exploration Program is intended to advance exploration of five of F4's uranium mineral properties (collectively, the "Exploration Properties") consisting of Todd Lake, Wales Lake East and Wales Lake West, located in the western Athabasca Basin region of Saskatchewan and all within 30 kilometres (km) of Paladin Energy Limited's Triple R and NexGen Energy Limited's Arrow projects, Cree Bay, located in the northern Athabasca Basin with encouraging pervious drill results and Grey Island, located in the eastern Athabasca Basin approximately 50 km west of the Key Lake Mine. The Exploration Program is anticipated to commence in or around July 2025 and shall consist of the following: Todd Lake: A ground electromagnetic (EM) survey to define drill targets by focusing on anomalies identified by airborne surveys. The Todd Lake property is situated in the historically underexplored Clearwater Domain which has been significantly upgraded by F3 Uranium Corp.'s ("F3") recent discovery of radioactivity at the "PW" area, less than 10 km to the northeast of the Todd Lake property. Wales Lake East: Drilling of two holes to test priority conductivity. Wales Lake West: Drilling of three holes to test priority conductivity targets and additional airborne VTEM surveys and subsequent follow-up ground EM. Cree Bay - Mobile MT airborne geophysical survey to better identify structural corridors by enhancing previous airborne VTEM and ground EM geophysics carried out on the Cree Bay property. Two 2019 drill holes intersected wide structures in the Athabasca Sandstone with anomalous uranium geochemistry highlighting the potential for uranium mineralization on the Cree Bay property. Grey Island - Mobile MT airborne geophysical survey as the first phase of exploration on the Grey Island property to develop exploration targets. The Private Placement The gross proceeds from the Private Placement will be used by the Company to incur "Canadian exploration expenses" that qualify as "flow-through critical mineral mining expenditures" as such terms are defined in the Tax Act, and to incur "eligible flow-through mining expenditures" pursuant to The Mineral Exploration Tax Credit Regulations, 2014 (Saskatchewan) (collectively, the "Qualifying Expenditures") related to the Company's Exploration Program on the Exploration Properties. The Company intends to incur the Qualifying Expenditures on or before December 31, 2026, and renounce such Qualifying Expenditures in favour of the subscribers of the FT Shares effective December 31, 2025. Red Cloud Securities Inc. (the "Finder") will act as a finder for the Company in respect of the Private Placement on a best-efforts basis. As compensation for its services, the Finder will receive cash compensation equal to 6% of the gross proceeds of the Offering raised by the Finder. The Finder will also receive non-transferable common share purchase warrants (the "Finder Warrants") which will entitle the Finder to acquire such number of common shares of the Company ("Common Shares") as is equal to 6% of the number of FT Shares placed by the Finder. The Finder Warrants will be exercisable at a price of $0.10 per Common Share at any time for a period of 24 months following the closing date of the Private Placement. The Private Placement is scheduled to close on or about June 18, 2025, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The FT Shares to be issued under the Private Placement, the Finder Warrants and any Common Shares issued upon the exercise thereof will be subject to a statutory hold period of four months and one day from the closing date of the Private Placement. It is anticipated that certain directors, officers and other insiders of the Company may acquire FT Shares under the Private Placement. Such participation will be considered to be "related party transactions" within the meaning of TSX Venture Exchange Policy 5.9 (the "Policy") and Multilateral Instrument 61-101-Protection of Minority Security Holders in Special Transactions ("MI 61-101") adopted in the Policy. The Company intends to rely on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Private Placement as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves interested parties, is expected to exceed 25% of the Company's market capitalization (as determined under MI 61-101). Qualified Person The technical information in this news release has been reviewed and approved on behalf of the Company by Sam Hartmann, President & Chief Operation Officer of F4, and a qualified person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. About F4 Uranium Corp: F4 is a uranium project generator and exploration company, focusing on projects in the Athabasca Basin, home to some of the world's largest high grade uranium discoveries. F4 currently has 17 projects in the Athabasca Basin, several of which are near large uranium discoveries including Triple R, Arrow and Hurricane. F4 has entered into option agreements on several of its properties which call for the applicable optionors to make cash payments and issue shares to F4, as well as to incur exploration expenditures on the properties in which they have been granted the option to earn an interest. Contact Information F4 Uranium Corp.750-1620 Dickson AvenueKelowna, BC V1Y9Y2 Investor RelationsTelephone: 778 484 8030Email: ir@ Forward Looking Statements This news release contains "forward-looking statements" and "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements in this news release relate to, among other things: the Company's strategic plans; the Company's proposed Exploration Program at the Exploration Properties, including the timing of commencement of the Exploration Program and the anticipated objectives and results therefrom; the anticipated closing of the Private Placement; the commissions payable to the Finder; the net proceeds from the Private Placement and the intended use therefrom; and the intention and timing related to incurring Qualifying Expenditures and the renunciation thereof. These forward-looking statements reflect the Company's current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include, among other things: conditions in general economic and financial markets; accuracy of assay results; geological interpretations from drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; the historical basis for current estimates of potential quantities and grades of target zones; the availability of skilled labour and no labour related disruptions at any of the Company's operations; no unplanned delays or interruptions in scheduled activities; all necessary permits, licenses and regulatory approvals for operations are received in a timely manner; the ability to secure and maintain title and ownership to properties and the surface rights necessary for operations; and the Company's ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive. The Company cautions the reader that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements contained in this news release and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; general market and industry conditions; and those factors identified under the caption "Risks Factors" in the Company's Listing Application on Form 2B. Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit
Yahoo
17 minutes ago
- Yahoo
Watch These CrowdStrike Price Levels as Stock Drops From Record High on Light Outlook
CrowdStrike shares tumbled on Wednesday after the cybersecurity provider issued a quarterly outlook below Wall Street estimates. The stock broke out from an ascending triangle to hit an all-time high earlier this week in a move that coincided with the relative strength index nudging toward overbought territory. Longer-term bullish momentum was tested on Wednesday. Investors should watch major support levels on CrowdStrike's chart around $455, $390 and $340, while also monitoring a key overhead area near $ (CRWD) shares retreated from their record high on Wednesday after the cybersecurity provider issued a disappointing quarterly revenue outlook. The company reported better-than-expected earnings for its latest quarter and announced a share repurchase program of up to $1 billion. However, CrowdStrike's guidance of fiscal second-quarter revenue of $1.14 billion to $1.15 billion came in below Wall Street Expectations. CrowdStrike shares fell nearly 6% to around $461 on Wednesday, leading Nasdaq decliners. Even with the sharp decline, the stock has gained 50% over the past 12 months, as the cybersecurity giant has recovered from an erroneous software update last July that caused a widespread outage of Windows PCs. Below, we take a closer look at CrowdStrike's chart and use technical analysis to identify major price levels worth watching out for. After forming two closely aligned troughs just below the 200-day moving average, CrowdStrike shares have trended sharply higher, albeit on lackluster trading volume. The stock broke out from an ascending triangle to an all-time high this week in a move that coincided with the relative strength index nudging toward overbought territory. However, longer-term bullish momentum was tested on Wednesday following the cybersecurity provider's soft outlook. Let's identify three major support levels on CrowdStrike's chart where the shares may encounter support and also locate a key overhead area to monitor if the stock resumes its longer-term uptrend. The first lower level to watch sits around $455. This area on the chart would likely provide significant support near the ascending triangle's top trendline and the prominent February swing high. A close below this level could see the shares retrace to the $390 level. The shares may attract support in this location near a trendline that links several peaks that formed on the chart between December and April. Further selling opens the door for a drop to lower support around $340. Investors could see this region, which sits just above the notable March and April troughs, as a longer-term floor given its proximity to a series of lows that developed on the chart from late November to early January. If CrowdStrike shares resume their longer-term uptrend, investors can project an overhead area to monitor by using the measured move technique, also known as the measuring principle. When applied to CrowdStrike's chart, we calculate the distance between the ascending triangle's two trendlines near this widest point and add that amount the pattern's breakout area. For example, we add $55 to $455, which projects a target of $510. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia
